

# 2021 Centers for Medicare & Medicaid Services (CMS) Clinical Star Ratings Measures\*

CMS Weight	CarePlus Weight†	Measure	Measure description	Exclusions	Age	Can be SATISFIED by telehealth (includes audio only)	Can be SATISFIED with an in-home test kit
1.0	1.0	Transitions of Care – Medication reconciliation post-discharge (MRP)	Medications reconciled from the date of discharge through 30 days after discharge (31 total days) <b>Date range:</b> Jan. 1 through Dec. 1	Patients in hospice	≥ 18	Yes	No
Display*	0	Transitions of Care – Patient Engagement After Inpatient Discharge	Documentation of patient engagement (e.g., office visits, visits to the home, telehealth) provided within 30 days after discharge <b>Date range:</b> Jan. 1 through Dec. 1				
Display*	0	Transitions of Care – Notification of Inpatient Admission	Documentation of receipt of notification of inpatient admission on the day of admission through two days after the admission (three total days) <b>Note:</b> Administrative reporting is not available for this indicator <b>Date range:</b> Jan. 1 through Dec. 1	Patients in hospice	≥ 18		
Display*	0	Transitions of Care – Receipt of Discharge Information	Documentation of receipt of discharge information on the day of discharge through two days after the discharge (three total days) <b>Note:</b> Administrative reporting is not available for this indicator <b>Date range:</b> Jan. 1 through Dec. 1				
1.0	1.0	Controlling blood pressure (CBP)***	Patients with a hypertension diagnosis with adequately controlled blood pressure (< 140/90 mm Hg) <b>Date range:</b> January through December (one year)	Palliative care, patients in hospice; patients 66–80 years of age with frailty and advanced illness; or patients 81 years of age or older with frailty	18 to 85	Yes <sup>4</sup>	No
1.0	1.0	Breast cancer screening (BCS)**	Breast cancer screening by mammography <b>Date range:</b> Oct. 1, 2019 – Dec. 31, 2021 (27-month lookback)	Palliative care, patients who have had a bilateral mastectomy or who have had both a unilateral left and unilateral right mastectomy; in hospice; or patients 66–74 years of age with frailty and advanced illness and/or living long term in an institutional setting	50 to 74	Yes <sup>1</sup>	No
1.0	1.0	Colorectal cancer screening (COL)**	iFOBT/gFOBT or <b>Date range:</b> January through December (one year)	Patients in hospice; patients who have had total colectomy or colorectal cancer; patients 66 to 75 years of age living long term in an institutional setting and/or with frailty and advanced illness	50 to 75	Yes <sup>1</sup>	Yes
	Sigmoidoscopy or <b>Date range:</b> current measurement year or previous four years						
	CT colonography or <b>Date range:</b> current measurement year or previous four years						
	Colonoscopy or <b>Date range:</b> current measurement year or previous nine years						
	Cologuard test <b>Date range:</b> current measurement year or previous two years						
1.0	1.0	Osteoporosis management in women who had a fracture (OMW)**	Women who suffered a fracture between July 1, 2020, and June 30, 2021, and completed a bone mineral density test (DEXA) and/or have a prescription filled for medication to treat/prevent osteoporosis within six months of the fracture date; or, who had a bone mineral density test within two years and/or a prescription filled for medication to treat/prevent osteoporosis within one year prior to the fracture date <b>Date range:</b> July 1, 2019 – Dec. 31, 2021, for a DEXA scan and/or prescription filled for medication to treat/prevent osteoporosis July 1, 2020 – Dec. 31, 2021	Palliative care, patients who had a bone mineral density test within two years and/or a prescription filled for medication to treat/prevent osteoporosis within one year prior to the fracture date; patients in hospice; patients 66–85 years of age living long term in an institutional setting; patients 67–80 years of age with frailty and advanced illness; or patients 81–85 years of age with frailty	67 to 85	No	No
1.0	1.0	Statin therapy for patients with cardiovascular disease (SPC)	Patients who were identified as having clinical atherosclerotic cardiovascular disease (ASCVD) and were dispensed at least one high- or moderate-intensity statin medication during the measurement year and remained on a high- or moderate-intensity statin medication for at least 80% of the treatment period <b>Date range:</b> January through December (one year)	Palliative care, patients in hospice; patients 66–75 years of age with frailty and advanced illness and/or living long term in an institutional setting; with services or diagnoses in prior or current year for pregnancy, in-vitro fertilization (IVF), dispensed clomiphene medication, end-stage renal disease (ESRD) or cirrhosis; or with diagnoses in current year for myalgia, myositis, myopathy or rhabdomyolysis	Men 21 to 75; women 40 to 75	No <sup>5</sup>	No <sup>5</sup>
Display*	1.0	Plan all-cause readmissions (PCR)	Patients readmitted for any diagnosis within 30 days of an acute inpatient stay <b>Date range:</b> January through December (one year)	Pregnant women and patients in hospice	≥ 18	No	No
<b>Comprehensive diabetes care (CDC) — patients are identified with type 1 or type 2 diabetes based on diagnoses submitted on claims in the year prior to the current measurement year</b>							
3.0	3.0	Comprehensive diabetes care – blood sugar controlled (CDC2_HBAPOOR)***	Eligible diabetic patients who have evidence of an HbA1c test with a level ≤ 9%; reports will include patients with HbA1c poor control (> 9%) <b>Date range:</b> January through December (one year)			Yes <sup>1</sup>	Yes <sup>2</sup>
1.0	1.0	Comprehensive diabetes care – eye exam (CDC2_EYE)**	Annual diabetic retinal exam (DRE) performed or evidence of negative DRE performed during the measurement year or the prior year (patients with bilateral eye enucleation are compliant) <b>Date range:</b> January through December (one year) for DRE performed in 2021; or Jan. 1, 2020 – Dec. 31 2021, for evidence of negative retinopathy	Palliative care, patients in hospice or patients 66–75 years of age with frailty and advanced illness and/or living long term in an institutional setting	18 to 75	Yes <sup>1</sup>	No
1.0	1.0	Comprehensive diabetes care – kidney disease monitoring (CDC2_NPH)	Diabetic patients receiving attention for nephropathy (albumin/protein test or documented evidence of nephropathy) <b>Date range:</b> January through December (one year)			Yes <sup>3</sup>	Yes
<b>Care for older adults (COA) — Special Needs Plan (SNP) members 66 and older and Medicare-Medicaid (dual-eligible) members</b>							
1.0	1.0	Care for older adults – medication review (COA_MDR)	Medication review (conducted by a practitioner with prescribing authority or clinical pharmacist) with the presence of a medication list in the medical record (need both to count) <b>Date range:</b> January through December (one year)			Yes	No
1.0	1.0	Care for older adults – pain screening (COA_PNS)	Comprehensive pain assessment – pain screening during the measurement year <b>Date range:</b> January through December (one year)	Patients in hospice	SNP ≥ 66	Yes	No
Display*	1.0	Care for older adults – functional status assessment (COA_FSA)	Functional status assessment – functional status assessment during measurement year <b>Date range:</b> January through December (one year)				
<b>Part D measures</b>							
1.0	1.0	Comprehensive medication review (CMR)	Patients who had a pharmacist (or other healthcare professional) help them understand and manage their medications through a comprehensive medication review (CMR) within 60 days of medication therapy management (MTM) program enrollment <b>Date range:</b> January through December (one year)	Not applicable	≥ 18	Yes	No
1.0	1.0	Statin use in persons with diabetes (SUPD)	Patients who received at least two diabetic medication fills and also received a statin medication <b>Date range:</b> January through December (one year)	Patients in hospice or with ESRD	40 to 75	No <sup>5</sup>	No <sup>5</sup>
<b>Medication adherence – patients who fill/refill their prescriptions often enough to cover 80% or more (portion of days covered [PDC] more than 80%) of the time they are supposed to be taking the medications</b>							
3.0	3.0	Medication adherence – diabetes	Patients taking diabetes medication as directed (In this measure, diabetes medication means a biguanide drug, a sulfonylurea drug, a thiazolidinedione drug, a DPP-IV inhibitor, an incretin mimetic, a meglitinide or an SGLT2 inhibitor; patients who take insulin are not included) <b>Date range:</b> January through December (one year)	Patients who filled a prescription for insulin; patients in hospice or with ESRD		No	No
3.0	3.0	Medication adherence – hypertension	Patients taking blood pressure medication as directed (In this measure, blood pressure medication means an angiotensin-converting enzyme [ACE] inhibitor, an angiotensin receptor blocker [ARB] drug or direct renin inhibitor [DRI] drug) <b>Date range:</b> January through December (one year)	Patients who filled a prescription for sacubitril/valsartan; patients in hospice or with ESRD	≥ 18	No	No
3.0	3.0	Medication adherence – cholesterol	Patients taking cholesterol medication as directed (In this measure, cholesterol medication means a statin drug) <b>Date range:</b> January through December (one year)	Patients in hospice or with ESRD		No	No

<sup>1</sup> Can be satisfied during a telehealth visit when a patient-reported service is documented in a submitted medical record. <sup>2</sup> Can be satisfied with a returned hemoglobin A1c (HbA1c) test kit results of 9% or less. <sup>3</sup> Can be satisfied with a telehealth visit only if the telehealth visit is with a nephrologist. <sup>4</sup> Can be satisfied with a telehealth visit when the patient is using a remote monitoring device that digitally stores and directly transmits results to the provider for interpretation. Patients can also visually share the results by displaying the device, a screenshot of it or a printout. Patient-reported readings are also now acceptable for this measure. <sup>5</sup> Prescription written at the time of care may satisfy associated measure.

\* CarePlus weights are aligned with CarePlus' Star reports and the Star Rewards Program. Measure weights may differ from CMS weights and are subject to change.

(\*) CarePlus' measure classification, weights and thresholds may differ from CMS'. Please reference reports provided by the health plan.

(\*\*) CarePlus accepts supplemental data for this measure.

(\*\*\*) Last value captured either administratively or documented in the patient's medical record during the measurement year.

The HEDIS measure specifications were developed by and are owned by NCQA. The HEDIS measure specifications are not clinical guidelines and do not establish a standard of medical care. NCQA makes no representations, warranties, or endorsement about the quality of any organization or physician that uses or reports performance measures and NCQA has no liability to anyone who relies on such measure specifications. NCQA holds a copyright in these materials and can rescind or alter these materials at any time. These materials may not be modified by anyone other than NCQA. Use of the Rules for Allowable Adjustments of HEDIS to make permitted adjustments of the materials does not constitute a modification. Any commercial use and/or internal or external reproduction, distribution and publication must be approved by NCQA and are subject to a license at the discretion of NCQA. Any use of the materials to identify records or calculate measure results, for example, requires a custom license and may necessitate certification pursuant to NCQA's Measure Certification Program. Reprinted with permission by NCQA. © 2021 NCQA, all rights reserved. Limited proprietary coding is contained in the measure specifications for convenience. NCQA disclaims all liability for use or accuracy of any third-party code values contained in the specifications. The full text of this notice and disclaimer is available at <https://docushare-web.apps.cf.humana.com/Marketing/docushare-app?file=4274309>.

LEGEND			
	not calendar year		triple weighted
			display measure